

# 1,3-Dipolar Cycloaddition Reactions of Vinylcephalosporins with Diazoalkanes

János Pitlik\* [b], Tamás E. Gunda and István Miskolczi

Research Group for Antibiotics of Hungarian Academy of Sciences, H-4010 Debrecen,  
P.O. Box 70, Hungary, and BIOGAL Pharmaceutical Works, Debrecen, Hungary  
Received August 28, 1989

The vinylcephalosporin (**1**) undergoes a regio- and stereoselective 1,3-dipolar cycloaddition with diazo-methane to give novel cephalosporins, a 3-pyrazolinocephem (**4**) and a double adduct (**5**). The vinylcephalosporin sulphoxide (**2**) gives only the pyrazolinocephem (**7**). In the reaction with diphenyldiazomethane upon heating the initially formed pyrazolines decompose and cyclopropylcephalosporin (**9**) formation takes place. The determination of the structures and stereochemistry of these compounds is also described.

*J. Heterocyclic Chem.*, **27**, 1281 (1990).


In our laboratory we study the cycloaddition reactions of cephalosporin compounds. We found that the  $\Delta^3$  double bond of cephems is relatively unreactive towards diazoalkanes [2]. The reaction was complete only after several days even with the most reactive diazomethane when 3,4-pyrazolinocepham formation took place. Bulky diazoalkanes, such as diphenyldiazomethane and ethyl diazoacetate do not undergo this cycloaddition.

In the reactions of 2-methylenecephalosporins with a range of diazoalkanes [3] the initially formed pyrazolines decomposed to 2-spirocyclopropylcephalosporins and the reactions were complete after 5 to 30 minutes at  $-5^\circ$  and in a highly stereoselective manner. The endo double bond of the dihydrothiazine moiety remained intact.

In this paper we report a novel utilisation of the

3-vinylcephalosporins and diazoalkanes. Our aim was to establish the possible regio- and stereoselective nature of these cycloadditions.

When we consider the similarities between the conjugated system of our starting materials, the vinylcephems (**1** and **2**) (Scheme 1) and that of the 2-methylenecephalosporins (Figure 1) we can expect that the sterically less hindered vinyl double bond of vinylcephems undergoes 1,3-dipolar cycloadditions with different diazoalkanes more easily and less selectively than the exo double bond of the 2-methylenecephems. Surprisingly, this is not in the case.



1,3-dipolar cycloadditions in cephalosporin chemistry where new types of cephalosporins form in the reaction of




Figure 1. The conjugated system of vinylcephalosporins (**b**) and 2-methylenecephalosporins (**a**).

When compound **1** (Scheme 1), prepared by literature methods [4], was allowed to react with a large excess of diazomethane at room temperature there was a single product after 5 minutes (tlc) but before completion of the reaction (1 hour) the formation of two additional products was observed in differing amounts.

In the  $^1\text{H}$  nmr spectrum of the initially formed (major) product the signals of vinyl hydrogens were not observable and five multiplets appeared (Table 2) (compound **4**). Couplings were observed among all of the new protons (COSY) showing that they are not separated by the  $-\text{N}=\text{N}-$  bond, *i.e.* the molecule is not an " $\alpha$ -adduct" of type **3**. However, these data did not preclude the possibility of a cyclopropane structure (**6**). The  $^{13}\text{C}$  nmr spectrum of the molecule (Table 3) contains two new signals in the region of  $=\text{N}-\text{CH}_2$  ( $\delta$  37-58) and one other in the region of  $-\text{C}-\text{CH}_2$  ( $\delta$  21-45) in spite of the signals of vinyl carbons. Based on

Table 1  
Physical and Analytical Data for Cephalosporins 1, 2, 4, 5, 7 and 9

Compound	mp, °	Yield, %	Molecular Formula	Analyses, %			IR, cm <sup>-1</sup> (β-lactam)
				Calcd./	(Found)		
				C	H	N	
1	196-197	52	C <sub>30</sub> H <sub>26</sub> N <sub>2</sub> O <sub>4</sub> S	70.59 (70.63)	5.09 (5.13)	5.49 (5.27)	1780
2	213-215	97	C <sub>30</sub> H <sub>26</sub> N <sub>2</sub> O <sub>5</sub> S	68.44 (68.56)	4.94 (4.96)	5.32 (5.29)	1780
4	104-107	34.3	C <sub>31</sub> H <sub>28</sub> N <sub>4</sub> O <sub>4</sub> S	68.11 (67.98)	5.07 (5.11)	10.14 (10.21)	1785
5	111-115	19.8	C <sub>32</sub> H <sub>30</sub> N <sub>6</sub> O <sub>4</sub> S	64.65 (64.52)	5.05 (5.19)	14.14 (14.03)	1785
7	221-223	A:87.5 B:62.5	C <sub>31</sub> H <sub>28</sub> N <sub>4</sub> O <sub>5</sub> S	65.49 (65.53)	4.93 (5.12)	9.86 (9.70)	1790
9a,b	87-90	30.2	C <sub>43</sub> H <sub>36</sub> N <sub>2</sub> O <sub>4</sub> S	76.33 (76.21)	5.32 (5.41)	4.14 (4.08)	1780 (broad)

Table 2  
<sup>1</sup>H NMR and MS Data for Compounds 1, 2, 4, 5, and 9

Compound	<sup>1</sup> H nmr [a], ppm	MS
1	3.3 and 3.6 (ABq, 2H, SCH <sub>2</sub> ), 3.56 (s, 2H, G-CH <sub>2</sub> ), 4.9 (d, 1H, H <sub>6</sub> ), 5.24 (d, 1H, vinyl-CH <sub>2</sub> -H <sub>A</sub> ), 5.39 (d, 1H, vinyl-CH <sub>2</sub> -H <sub>B</sub> ), 5.83 (dd, 1H, H <sub>7</sub> ), 6.64 (d, 1H, NH), 6.9 (s, 1H, BH), 7.0 (dd, 1H, vinyl-CH), 7.1-7.5 (m, 15H, arom)	ei: 510, (M <sup>+</sup> )
2	3.5 and 4.4 (ABq, 2H, SCH <sub>2</sub> ), 3.55 and 3.7 (ABq, 2H, G-CH <sub>2</sub> ), 4.95 (d, 1H, H <sub>6</sub> ), 5.35 (d, 1H, vinyl-CH <sub>2</sub> -H <sub>A</sub> ), 5.6 (d, 1H, vinyl-CH <sub>2</sub> -H <sub>B</sub> ), 5.9 (dd, 1H, H <sub>7</sub> ), 6.9 (dd, 1H, vinyl-CH), 6.95 (s, 1H, BH), 7.1-7.55 (m, 15H, arom), 8.52 (d, 1H, NH)	ei: 526 (M <sup>+</sup> )
4	1.1 and 2.1 (m, 2H, 4'-CH <sub>2</sub> ), 2.8 and 3.7 (ABq, 2H, SCH <sub>2</sub> ), 3.75 and 3.85 (ABq, 2H, G-CH <sub>2</sub> ), 4.05 and 4.9 (m, 2H, 5'-CH <sub>2</sub> ), 5.05 (d, 1H, H <sub>6</sub> ), 5.2 (m, 1H, 3'-CH), 5.9 (dd, 1H, H <sub>7</sub> ), 6.05 (d, 1H, NH), 6.95 (s, 1H, BH), 7.1-7.3 (m, 15H, arom)	ci: 553 (M <sup>+</sup> +1)
5	0.9-1.1 (m, 2H, 4'-CH <sub>2</sub> ), 1.75 and 1.95 (ABq, 2H, SCH <sub>2</sub> ), 3.8 (s, 2H, G-CH <sub>2</sub> ), 3.95 and 4.5 (m, 3H, 5'-CH <sub>2</sub> +3'-CH) 4.85 (d, 1H, H <sub>6</sub> ), 5.45 and 5.65 (ABq, 2H, 5''-CH <sub>2</sub> ), 5.6 (dd, 1H, H <sub>7</sub> ), 6.05 (d, 1H, NH), 6.95 (s, 1H, BH), 7.1-7.3 (m, 15H, arom)	ei: 566 (M <sup>+</sup> -28) Fab: 594 (M <sup>+</sup> )
7	1.1 and 2.1 (m, 2H, 4'-CH <sub>2</sub> ), 2.97 and 3.25 (ABq, 2H, SCH <sub>2</sub> ), 3.55 (s, 2H, G-CH <sub>2</sub> ), 4.02 and 4.78 (m, 2H, 5'-CH <sub>2</sub> ), 4.52 (d, 1H, H <sub>6</sub> ), 5.43 (m, 1H, 3'-CH), 6.09 (dd, 1H, H <sub>7</sub> ), 6.95 (s, 1H, BH), 7.05-7.5 (m, 15H, arom)	ei: 568 (M <sup>+</sup> )
9a,b	9a: 1.39, 1.74 and 3.77 (3t, 3H, cyclopropyl-Hs), 1.96 and 2.84 (ABq, 2H, SCH <sub>2</sub> ), 3.57 (s, 2H, G-CH <sub>2</sub> ), 4.4 (d, 1H, H <sub>6</sub> ), 5.6 (dd, 1H, H <sub>7</sub> ), 6.5 (d, 1H, NH), 6.9-7.8 (m, 31H, NH+arom) 9b: 1.42, 1.65 and 2.9 (3t, 3H, cyclopropyl-Hs), 2.14 and 2.63 (ABq, 2H, SCH <sub>2</sub> ), 3.55 (s, 2H, G-CH <sub>2</sub> ), 4.7 (d, 1H, H <sub>6</sub> ), 5.6 (dd, 1H, H <sub>7</sub> ), 6.1 (d, 1H, NH), 6.9-7.8 (m, 31H, NH+arom)	ei: 676 (M <sup>+</sup> )

[a] In the case of 1, 4, 5, 7 and 9 the solvent was deuteriochloroform and in the case of 2 dimethyl-d<sub>6</sub> sulphoxide.

these findings the structure of the initially formed main product is **4**. The ms and elemental analyses (Table 1 and 2) corroborated this establishment. Only one of the two possible C-3' stereoisomers was formed in a quantitatively **stereoselective** reaction. The molecule is a "β-adduct" (**4**) (the new carbon-carbon bond formed at the β-position to carbon C-3), *i.e.* the reaction is **regioselective**. This was expected by the FMO-theory [5], too.

The <sup>1</sup>H and <sup>13</sup>C nmr spectra of the other major product is very similar to those of **4** but both contain a new -CH<sub>2</sub>-signal characteristic of 3,4-pyrazolinocephams indicating the pyrazolino-pyrazolylcepham (**5**) structure of the molecule. In the light of our earlier findings [2] this fast reaction of the Δ<sup>3</sup> bond was unexpected. Isomerisation of the -N=N- double bond did not take place [2,6].


Unfortunately, the minor product of the reaction was not formed in sufficiently large amount to rigorously

establish the structure but the <sup>1</sup>H nmr spectrum of the molecule is very similar to that of **5**, indicating that these compounds are probably different only in the configurations at C-3 and C-4.

In order to gain further insight into the nature of the cycloaddition, the vinylcephalosporin sulphoxide (**2**) was also prepared. This compound underwent cycloaddition reaction with diazomethane only after 4 hours and a single product (**7**) was observed in a **stereo- and regioselective** reaction. This molecule was identical with the peracid oxidation product of **4**. Double adduct (**8**) did not form.

The stereochemistry at C-3' depends upon the direction of attack of diazomethane. The β-face of the cephalosporin molecule can be regarded as the *re*-side of the dienophile. As it is seen from Figure 2 [7], there is a 4% nOe between 2β-H and one of the pyrazoline 4'-H protons. This information alone is not enough to elucidate the

Table 3

 $^{13}\text{C}$  NMR Data for the Cephalosporins 1, 2, 4, 5, 7 and 9

Number	1	2	3	4	5	6	7	8	9	10	11	12	13	14
1	24.11	133.86	124.23	57.66	59.29	129.42	117.98							
2	37.14	134.58	124.31	65.09	58.43	130.38	119.76							
4	23.53	135.67	124.05	57.93	58.98	-	-	87.68	22.52	76.67				
5	27.62	104.87	46.82	55.06	60.49	-	-	90.63	19.76	76.85	-	-	-	87.89
7	44.02	133.97	123.84	67.09	58.99	-	-	88.07	23.58	76.74				
9a	26.31	133.06	125.81	57.50	58.92	-	-	-	-	-	27.57	18.82	37.75	
9b	26.31	133.06	125.81	58.21	58.92	-	-	-	-	-	28.70	18.82	37.75	




Figure 2. The possible C-3 *R* (a) and *S* (b) configurations of compound 4, resulted from the  $\beta$  and  $\alpha$  face attack of  $\text{CH}_2\text{N}_2$ . The most important nOe value is also shown. For clarity, the 7-acylamido side-chain and the benzhydryl moiety of 4-ester group are omitted.

stereochemistry at C-3'. A simple molecular modelling experiment shows that on rotating the pyrazoline ring around the C-3 - C-3' axis, the two hydrogens are in close contact of about 1.75 Å after the minimalization of conformational energy. This is smaller than the sum of the VDW radii. Moreover, the bulky C-4 ester group totally restricts the rotation of the pyrazoline group. Figure 3 shows the relative energy changes vs  $\Theta$  dihedral angle (C-4 - C-3 - C-3' - C-4') for C-3 *R* and *S* isomers. The above mentioned nOe could be observed in two conformations of each of the stereoisomers, respectively. The markings on the energy curves of Figure 3 correspond to  $\Theta$  values of these conformers and reveal that the adoption of a suitable conformation in the case of *R* isomer (■) is far less favourable than that in the *S* isomer (x). Thus we can deduce that the molecules 4 and 7 have probably the C-3'*S* configuration (Structure b, Figure 2) and they are formed by the attack of the diazomethane from the less hindered  $\alpha$ -face of the cephalosporin in completely stereoselective reactions.

The determination of structure of 5 was more difficult

Figure 2




Figure 3. Changes in conformational energy when the 3-pyrazolyl group is rotated around the C-3 - C-3' axis in 4. At the high energy values the pyrazolyl and ester groups conflict. The smaller peaks show the close contact of 2-H and 4'-H atoms shaded on Figure 1.

because the  $^1\text{H}$  nmr spectrum of the molecule contains a lot of resonances making difficult the selective irradiation of the different hydrogens during a nOe experiment. The nOe data reveal that there is 6.5% nOe enhancement on one of the 3,4-pyrazolino-methylene hydrogens when the C-3'-CH was irradiated. As the C-3' configuration is the same for both 4 and 5 this result suggest that the 3,4-pyrazolino hydrogens and the C-3'-CH are in close pro-

ximity to each other in space, *i.e.* on the same side of the molecule and the compound **5** has 3*R*,4*S*,3'*S*-configuration (Figure 4).




Figure 4. Computer aided design of the structure of the pyrazolinopyrazolilcepham (**5**), which corresponds to the observed nOe between 3'*H* and 5''-*H*<sub>exo</sub>.

Surprisingly, the 1,3-dipolar cycloadditions of the vinylcephalosporin (**1**) with diphenyldiazomethane occurred only after 40 hours reflux in dichloromethane to give two products, the two epimers of **9**. They formed in a ratio 2:1

(**9a**:**9b**). The  $\Delta^3$  double bond of the molecule was unaffected in this reaction, neither pyrazolinopyrazolilcephalosporin of type **5** nor compound **10** (Scheme 1) formed.

All of the characterising experiments (nmr, ms, *etc.*) were carried out with the mixture of the epimers. The data from the nOe experiment on the main product (**9a**) is shown in Figure 5. By virtue of these data Structure **b** (Figure 5) is also possible but it was precluded owing to the steric hindrance between the carboxyl group of the cephalosporin nucleus and a phenyl group of the cyclopropane moiety. Thus we can state the structure of the main product (**9a**) is that shown in Figure 5 (Structure **a**) and has the C-1'*S* configuration. The molecule is a result of a less hindered  $\alpha$ -face attack of the diazoalkane. The minor product (**9b**) has the C-1'*R* configuration and is formed from the more crowded  $\beta$ -face approach of the diphenyldiazomethane. The most likely structure of this product is shown in Figure 5 (Structure **c**).

The cyclopropylcephalosporins (**9**) did not undergo further cycloadditions with different diazoalkanes to give compounds of type **10**, nor did these types of compounds form from the compound **5** upon heating [8].




Figure 5. Possible conformations of **9a** and **9b**. In the case of *S* isomer (**a**) (assigned to **9a**) the molecule can adopt the conformation according to the observed nOe values, but not that of the *R* isomer (**b**).

## EXPERIMENTAL

Melting points were determined on a PHMK hot plate apparatus and are uncorrected. The infrared spectra were recorded in potassium bromide discs on a Perkin Elmer 283B instrument. The  $^1\text{H}$  and  $^{13}\text{C}$  nmr spectra were recorded on a Bruker VD 200SY and a Varian Gemini 200 200 MHz spectrometers in deuteriochloroform, perdeuteriobenzene and dimethyl- $d_6$  sulphoxide solution with tetramethylsilane as internal standard. Ms spectra were obtained on a VG 7035 GC-MS and on a ZAB-1F mass spectrometers. Microanalyses were performed on a Carlo Erba Strumentazione Elemental Analyser, model 1106 interfaced to a Commodore 8296-D computer and in the Microanalysis Laboratory of the Kossuth University of Debrecen. For tlc purposes Merck DC Alurolle Kieselgel 60F 254 was used (uv light, iodine vapour visualisation).

Benzhydryl 7-Phenylacetamido-3-vinyl-3-cephem-4-carboxylate (**1**).

Compound **1** was prepared from 7-aminocephalosporanic acid using literature methods [4] without any modification. Recrystallisation was carried out from a mixture of acetone and water. The physical data are shown in Tables 1 and 2.

Benzhydryl 7-Phenylacetamido-3-vinyl-3-cephem-4-carboxylate 1*S*-( $\beta$ )-Oxide (**2**).

Vinylcephalosporin **1** (2 g, 3.9 mmole) was dissolved in 200 ml of dichloromethane. The solution was cooled to a maximum  $5^\circ$  and the treated dropwise with 0.8 g (4.2 mmole, 90% activity) of 3-chloroperbenzoic acid dissolved in 30 ml of dichloromethane. After stirring for 30 minutes the reaction mixture was washed with 10% sodium hydrogen carbonate solution and water, dried over anhydrous magnesium sulphate and concentrated to 30 ml and cooled. The white powder precipitated was recrystallized from a mixture of acetone and water (Tables 1 and 2).

Benzhydryl 7-Phenylacetamido-3-(3'-pyrazolyl)-3-cephem-4-carboxylate (**4**) and Benzhydryl 7-Phenylacetamido-3-(3'-pyrazolyl)-3,4-(4'',3''-pyrazolino)cepham-4-carboxylate (**5**).

Compound **1** (1 g, 2 mmole) was dissolved in 20 ml of dichloromethane and cooled to  $0^\circ$  and a large excess of diazomethane (prepared from 5 g of *N*-nitroso-*N*-methylurea) in 100 ml of diethyl ether was added to this solution. After 1 hour reaction time the solvents were removed in vacuum and the oily residue was chromatographed (Tables 1 and 2).

Benzhydryl 7-Phenylacetamido-3-(3'-pyrazolyl)-3-cephem-4-carboxylate 1*S*-( $\beta$ )-Oxide (**7**).

Method A.

Compound **4** (0.2 g, 0.4 mmole) was dissolved in 30 ml of

dichloromethane and cooled to  $0^\circ$ . To this solution 0.14 g (0.44 mmole, 55% activity) of 3-chloroperbenzoic acid in 20 ml of dichloromethane was dropwise added. After stirring for 30 minutes the reaction mixture was washed with 10% sodium hydrogen carbonate solution and water, dried over anhydrous magnesium sulphate and cooled. A white powder precipitated.

Method B.

To a solution of vinylcephalosporin sulphoxide **2** (0.1 g, 0.19 mmole) in 20 ml of dichloromethane a large excess of diazomethane (from 2 g *N*-nitroso-*N*-methylurea) in 50 ml of dichloromethane was added. The reaction was followed by tlc. After 4 hours a single product formed which was identical with the product of method A ( $^1\text{H}$  nmr, tlc) (Tables 1 and 2).

Benzhydryl 7-Phenylacetamido-3-(2',2'-diphenylcyclopropyl)-3-cephem-4-carboxylate (**9a** and **9b**).

Vinylcephalosporin **1** (1 g, 2 mmole) was dissolved in 20 ml of dichloromethane and 0.6 g (3 mmole) of diphenyldiazomethane was added. The reaction mixture was refluxed for 40 hours. The solvent was removed and the oily residue chromatographed (Tables 1 and 2).

Acknowledgements.

The authors would like to thank Professor F. Sztaricskai for advice, K. E. Kövér, Gy. Batta and Z. Dinya for the excellent nmr and ms spectra and M. Bradley for reviewing this manuscript.

## REFERENCES AND NOTES

- [a] Dedicated to the memory of Professor Rezső Bognár.  
 [b] Present address: Dyson Perrins Laboratory, South Parks Road, Oxford OXI 3QY, UK.
- [1] Preliminary communication: J. Pitlik, I. Miskolczi, K. E. Kövér, J. Cs. Jászberényi and F. Sztaricskai, *Tetrahedron Letters*, **30**, 2005 (1989).  
 [2] E. R. Farkas, E. T. Gunda and J. Cs. Jászberényi, *Tetrahedron Letters*, 5127 (1973).  
 [3a] J. Cs. Jászberényi, J. Pitlik, K. E. Kövér, Gy. Batta and K. Kollár, *Magn. Reson. Chem.*, **26**, 658 (1988); [b] J. Pitlik and J. Cs. Jászberényi, *J. Heterocyclic Chem.*, **26**, 461 (1989).  
 [4] H. Yamanaka, T. Chiba, K. Kawabata, H. Takasugi, T. Masugi, and T. Takaya, *J. Antibiot.*, **38**, 1738 (1985).  
 [5] I. Fleming, *Frontier Orbitals and Organic Reactions*, John Wiley and Sons, London, 1976.  
 [6] R. A. Archer and B. S. Kitchell, *J. Org. Chem.*, **31**, 3409 (1966).  
 [7] The molecular geometries were refined with the program ALCHEMY (Tripos Associates, Inc.).  
 [8] J. H. Bateson, D. F. Corbett and R. Southgate, in *Recent Advances in the Chemistry of  $\beta$ -Lactam Antibiotics*, A. G. Brown and S. M. Roberts, eds, The Royal Society of Chemistry, Spec. Publ. No. 52, London, 1985, pp 116-130.